Compare TRT & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRT | ATRA |
|---|---|---|
| Founded | 1958 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 37.6M |
| IPO Year | N/A | 2014 |
| Metric | TRT | ATRA |
|---|---|---|
| Price | $5.60 | $4.55 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 82.3K | ★ 717.5K |
| Earning Date | 02-10-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.03 | ★ 1.97 |
| Revenue | $42,188,000.00 | ★ $151,930,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $163.26 | ★ $2.47 |
| Revenue Growth | 0.10 | ★ 51.27 |
| 52 Week Low | $2.31 | $4.20 |
| 52 Week High | $7.60 | $19.15 |
| Indicator | TRT | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 29.61 | 26.85 |
| Support Level | $5.25 | $4.91 |
| Resistance Level | $6.43 | $5.71 |
| Average True Range (ATR) | 0.43 | 0.44 |
| MACD | -0.03 | 0.23 |
| Stochastic Oscillator | 6.67 | 21.85 |
Trio-Tech International operates in the semiconductor industry, providing manufacturing, testing, and distribution services for semiconductor test equipment and electronic components. It has two main segments: Semiconductor Back-end Solutions (SBS) and Industrial Electronics (IE). The SBS segment, which generates the majority of the Company's revenue, focuses on manufacturing equipment for semiconductor back-end processes, offering testing services, and distributing burn-in test related equipment. The IE segment manufactures equipment for other industries and distributes electronic products outside the semiconductor sector. The Company operates in the United States, Singapore, Malaysia, Thailand, and China, serving customers across multiple regions.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).